Peptides for Weight Loss: Side Effects, Risks, and What to Watch For

The most common side effects of weight-loss peptides like semaglutide and tirzepatide are gastrointestinal: nausea, constipation, diarrhea, and cramping, which often ease within weeks. Less common effects include injection-site reactions, headache, fatigue, and low blood sugar. Rare but serious risks include pancreatitis, gallbladder disease, and FDA-labeled thyroid-tumor warnings.[1][2]

What are “peptides for weight loss,” exactly?

Peptides for weight loss is a broad phrase. In everyday search, it often means injectable medicines that act like gut hormones, especially GLP-1 medications, plus some non-approved “research peptides.” These groups are not the same, and their FDA status and safety evidence differ in important ways.[1][2][10]

GLP-1s and dual GIP/GLP-1 agonists

Semaglutide is the active ingredient in Wegovy and Ozempic. It is a GLP-1 receptor agonist, meaning it acts on GLP-1 receptors that help regulate appetite, blood sugar, and stomach emptying. Wegovy is FDA-approved for chronic weight management in certain patients; Ozempic is FDA-approved for type 2 diabetes, not weight loss.[1][3]

Tirzepatide is the active ingredient in Zepbound and Mounjaro. It is a dual GIP/GLP-1 receptor agonist, meaning it acts on two gut-hormone pathways. Zepbound is FDA-approved for chronic weight management in certain patients; Mounjaro is FDA-approved for type 2 diabetes, not weight loss.[2][4]

Liraglutide is the active ingredient in Saxenda, a GLP-1 receptor agonist FDA-approved for chronic weight management in certain patients. Like other drugs in this class, its benefits must be weighed against side effects such as nausea, vomiting, diarrhea, constipation, and possible gallbladder problems.[5]

Brand vs. generic vs. compounded versions

Brand-name products are FDA-approved only for the uses listed on their labels. Compounded semaglutide via a 503A pharmacy and compounded tirzepatide via a 503A pharmacy are different: they are prepared for individual patients by state-licensed pharmacies when legally allowed, but they are not FDA-approved products and are not reviewed by FDA for safety, effectiveness, or quality before dispensing.[8][9]

Research peptides vs. FDA-approved medications

Research peptides sold online may be marketed with weight-loss claims, but many are not FDA-approved for weight loss and may not have strong human safety data. Products sold for “research use only” are not the same as clinician-prescribed medications from regulated pharmacies.[10]

What are the most common side effects?

The most common side effects of semaglutide and tirzepatide are stomach-related. In FDA labels and large trials, nausea, diarrhea, vomiting, constipation, and abdominal pain were common, especially during dose increases or early treatment periods.[1][2][6][7]

Gastrointestinal effects: nausea, constipation, diarrhea

GLP-1 and GIP/GLP-1 medicines slow stomach emptying and affect appetite pathways. That is part of how they may support weight loss, but it also explains why nausea, fullness, reflux, constipation, diarrhea, and cramping can happen. In studies, these effects were often mild to moderate, but some people stopped treatment because of them.[6][7]

Injection-site reactions

Injection-site reactions can include redness, itching, bruising, or tenderness where the medicine is injected. FDA labels for GLP-1 and GIP/GLP-1 medications list injection-site reactions among possible adverse effects, along with rare allergic reactions that need urgent care.[1][2][5]

Headache, fatigue, and dizziness

Some people report headache, fatigue, dizziness, or feeling weak. These symptoms can overlap with lower food intake, dehydration, stomach upset, or low blood sugar in people also using insulin or sulfonylurea diabetes medicines. A clinician can help sort out the cause and decide what to do next.[1][2]

What are the serious but rare risks?

Serious side effects are uncommon, but they matter. FDA labels for GLP-1 and GIP/GLP-1 medicines include warnings about pancreatitis, gallbladder disease, hypoglycemia with certain diabetes drugs, kidney injury linked to dehydration, severe stomach problems, allergic reactions, and a boxed warning about thyroid C-cell tumors.[1][2][5]

Pancreatitis

Pancreatitis means inflammation of the pancreas. FDA labels advise stopping the medication and seeking medical care if pancreatitis is suspected, such as severe stomach pain that may spread to the back and may come with vomiting. People with a history of pancreatitis need a careful clinician review before use.[1][2][5]

Gallbladder problems

Gallbladder disease, including gallstones or cholelithiasis, has been reported with GLP-1 medicines. Rapid weight loss itself can also raise gallstone risk, so pain in the right upper belly, fever, yellowing skin, or persistent vomiting should be checked promptly.[1][2][11]

Thyroid C-cell tumor boxed warning

Semaglutide, tirzepatide, and liraglutide labels carry a boxed warning about thyroid C-cell tumors seen in rodents. It is not known whether these medicines cause medullary thyroid carcinoma in humans, but the labels say they should not be used in people with a personal or family history of medullary thyroid carcinoma or in people with multiple endocrine neoplasia syndrome type 2, often called MEN2.[1][2][5]

Hypoglycemia, especially with other diabetes medications

Hypoglycemia means low blood sugar. GLP-1 and GIP/GLP-1 medicines have a higher hypoglycemia risk when used with insulin or sulfonylureas. FDA labels advise clinicians to consider lowering the dose of those other diabetes medicines when starting therapy, but any medication change must be clinician-directed.[1][2][12]

How do side effects differ between semaglutide and tirzepatide?

Semaglutide and tirzepatide have overlapping side effects because both act on GLP-1 pathways. Tirzepatide also acts on GIP receptors. In large trials lasting about 68 to 72 weeks, both medicines were linked with meaningful weight loss, but also with stomach side effects and rare serious risks that require screening and follow-up.[6][7]

The table is a general comparison, not a way to choose a medication on your own. Your medical history, current medicines, side-effect tolerance, pregnancy plans, and treatment goals all matter.[1][2][5]

Who should not take weight-loss peptides?

Some people should avoid weight-loss peptides or use them only with close clinician review. FDA labels list clear contraindications and warnings, including thyroid cancer history, MEN2, pregnancy, certain allergies, pancreatitis concerns, and severe gastrointestinal disease.[1][2][5]

Personal or family history of medullary thyroid cancer or MEN2

Semaglutide, tirzepatide, and liraglutide should not be used by people with a personal or family history of medullary thyroid carcinoma or by people with MEN2. This warning comes from animal findings and is included in FDA boxed warnings.[1][2][5]

Pregnancy and breastfeeding

Weight-loss GLP-1 medications are not recommended during pregnancy, and FDA labels advise stopping before a planned pregnancy for some products because weight loss offers no benefit during pregnancy and may harm the fetus. Breastfeeding safety varies by product and should be reviewed with a clinician.[1][2][5]

History of pancreatitis or severe GI disease

People with a history of pancreatitis, gastroparesis, severe reflux, inflammatory bowel disease flares, or other major stomach-emptying problems need extra caution. These medicines can slow stomach emptying and may worsen symptoms in some people.[1][2]

Are non-GLP-1 peptides like BPC-157, AOD-9604, and CJC-1295 safe for weight loss?

BPC-157, AOD-9604, and CJC-1295/Ipamorelin are not FDA-approved for weight loss. They are often discussed online as “research peptides,” but online marketing is not the same as FDA review. Safety, purity, dose accuracy, and long-term effects may be unclear, especially when products are bought without a prescription or from non-pharmacy sources.[10]

BPC-157 is a synthetic peptide studied mostly in preclinical injury and gut models, not as an FDA-approved weight-loss drug. AOD-9604 is a modified growth-hormone fragment studied for fat metabolism, but it is not FDA-approved for obesity treatment. CJC-1295 and Ipamorelin affect growth-hormone signaling and are not FDA-approved for weight loss; possible risks include fluid retention, glucose changes, joint pain, and unknown long-term effects.[10][13]

Some non-GLP-1 peptides are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23-24, 2026. That review does not mean a peptide is approved, safe, or effective for weight loss; it means FDA’s pharmacy compounding advisory process is evaluating certain bulk substances.[10]

How can you reduce side effects during treatment?

Many side effects are related to how the body adjusts to GLP-1 treatment over time. A slower, clinician-guided titration plan, smaller meals, hydration, and early reporting of warning signs may reduce discomfort, but no strategy removes all risk.[1][2]

Slow dose titration

FDA-approved GLP-1 and GIP/GLP-1 medicines use gradual dose escalation schedules to help the body adjust. Do not change the timing, amount, or frequency of any medication without the prescribing clinician’s guidance.[1][2][5]

Eating and hydration strategies

Smaller meals, slower eating, limiting greasy foods, and drinking enough fluids may help some people manage nausea, constipation, or diarrhea. These steps are supportive, not a substitute for medical care if symptoms are severe, persistent, or worsening.[1][2]

When to call your clinician

Call a clinician promptly for severe or lasting stomach pain, repeated vomiting, signs of dehydration, fainting, symptoms of low blood sugar, yellowing skin, fever, neck swelling, trouble swallowing, or shortness of breath. Seek urgent care for symptoms that feel severe or rapidly worse.[1][2][5]

How can you get a clinician-reviewed prescription safely?

A safe path starts with a licensed clinician who reviews your body-mass index, health history, medications, pregnancy plans, prior pancreatitis or gallbladder disease, and symptoms of gastroparesis. If a prescription is appropriate, options may include FDA-approved brand medications or compounded GLP-1s prepared by licensed 503A pharmacies for individual patients when legally allowed.[1][2][8][9]

Chia is one telehealth option that offers clinician-reviewed access to compounded GLP-1s and longevity peptides through licensed pharmacy partners, with eligibility screening before prescribing. Other licensed clinicians, obesity medicine specialists, endocrinologists, and primary care teams can also help you decide whether treatment is appropriate.

Frequently asked questions

Keep reading

Weight Loss

Peptides for Weight Loss: How They Work and What to Know

GLP-1 Medications

GLP-1 Side Effects: What to Expect and How to Manage Them

Weight Loss

How to Get Weight Loss Medication: Eligibility, Options, and Costs